Search results
Results from the WOW.Com Content Network
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.
Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [1] The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. [ 1 ]
[1] [2] It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. [1] Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise. [1] It is taken by mouth, [1] reaching a peak effect within three hours and lasting for about a day. [1]
At 12 weeks, MAGE was significantly lower in the DPP-4 inhibitor groups (gemigliptin and sitagliptin) than in the glimepiride group (–43.1, –38.3, and –21.7 mg/dL, respectively). Furthermore, the SD of mean glucose was significantly lower in patients with gemigliptin when compared with sitagliptin (P=0.023) and glimepiride (P=0.0058).
Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study at the University of British Columbia.
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
DPP-4 inhibitors and GLP-1. Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]
This is the first class of non-opioid pain medication approved to treat moderate to severe acute pain approved by the FDA in more than 20 years. FDA approves new type of non-opioid pain medication ...